Suppr超能文献

侵袭性系统性肥大细胞增多症中的推测性肥大细胞脉络膜浸润

Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis.

作者信息

Tran Tu M, Najafi Mehdi, Ambros Tadeu, Pulido Jose S, Ustun Celalettin, Koozekanani Dara

机构信息

Department of Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN, USA.

Oncology/Hematology Service, Essentia Health, Fargo, ND, USA.

出版信息

Am J Ophthalmol Case Rep. 2020 Feb 4;18:100614. doi: 10.1016/j.ajoc.2020.100614. eCollection 2020 Jun.

Abstract

PURPOSE

To report a rare case of a unilateral choroidal mast cell infiltration in a patient with aggressive systemic mastocytosis (ASM).

OBSERVATIONS

The patient is a man in his fifties with a diagnosis of ASM. He developed visual complaints in the right eye associated with an area of subretinal fluid on fundus examination. Visual acuity at presentation was 20/150 in the right eye and 20/25 in the left eye. After ophthalmic and radiologic imaging workup, the patient was diagnosed with presumed choroidal mast cell infiltrate. The index of suspicion was high due to the prior ASM diagnosis. External beam radiation and intravitreal injection treatments were offered but the patient declined. The patient was switched from interferon to a new targeted systemic therapy for ASM, midostaurin. Despite some mixed, temporary response in systemic symptoms/signs of ASM at four months, the choroidal lesion and subretinal fluid were stable with visual acuity at 20/125.

CONCLUSION AND IMPORTANCE

Mast cell choroidal infiltration in ASM should be considered as part of the differential with acute/subacute vision changes. Diagnosis requires exclusion of other possibilities with ocular imaging and in this case, monitoring for development of other malignancies in which there were none. Midostaurin's ocular response was not on par with systemic response. Additional localized ocular therapies may be required.

摘要

目的

报告一例侵袭性系统性肥大细胞增多症(ASM)患者单侧脉络膜肥大细胞浸润的罕见病例。

观察结果

患者为一名五十多岁男性,诊断为ASM。他出现右眼视力问题,眼底检查发现视网膜下液区域。就诊时右眼视力为20/150,左眼视力为20/25。经过眼科和放射影像学检查,患者被诊断为疑似脉络膜肥大细胞浸润。由于之前的ASM诊断,怀疑指数很高。提供了外照射放疗和玻璃体内注射治疗,但患者拒绝了。患者从干扰素转换为一种新的针对ASM的靶向全身治疗药物米哚妥林。尽管在四个月时ASM的全身症状/体征有一些混合的、暂时的反应,但脉络膜病变和视网膜下液稳定,视力为20/125。

结论与意义

ASM中的肥大细胞脉络膜浸润应被视为急性/亚急性视力变化鉴别诊断的一部分。诊断需要通过眼部成像排除其他可能性,在本病例中,未发现其他恶性肿瘤。米哚妥林的眼部反应与全身反应不一致。可能需要额外的局部眼部治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa6/7021538/95f2b0f7add4/gr1.jpg

相似文献

本文引用的文献

2
New concepts in the diagnosis and management of choroidal metastases.脉络膜转移瘤的诊断和治疗新概念。
Prog Retin Eye Res. 2019 Jan;68:144-176. doi: 10.1016/j.preteyeres.2018.09.003. Epub 2018 Sep 19.
5
Ocular extramedullary myeloid leukaemia.
Br J Haematol. 2018 Mar;180(5):738-740. doi: 10.1111/bjh.14430. Epub 2016 Nov 23.
9
[Melanocytic choroidal changes in mastocytosis].
Klin Monbl Augenheilkd. 2009 Mar;226(3):193-4. doi: 10.1055/s-0028-1109158. Epub 2009 Mar 17.
10
Presumed choroidal and orbital mastocytosis.
Arch Ophthalmol. 2001 Nov;119(11):1716-9.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验